There is substantial experience attempting to treat KRAS-mutated lung adenocarcinoma with the use of RAS/RAF multikinase inhibitors as well as inhibitors of both upstream and downstream proteins important in RAS signaling. We review the disappointing results from these clinical trials in lung cancer. ...
EP: 8.KRAS G12C–Mutated NSCLC: Real-World Implications of Novel Targeted Therapy Transcript: Joshua K. Sabari, MD: Curious Martin, now that these drugs hopefully will be approved in the near future; sotorasib FDA approved, adagrasib going to be approved in mid-December of this year...
Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the need for treatment options in KRAS-mutated metastatic colorectal cancer (mCRC). KRAS mutations comprise about 50% of patients with mCRC. Patients with a KRAS mutation have 1 less therapeutic option because...
Conclusions Our real-life data regarding KRAS-mutated PDAC patients who received treatment with the MEK inhibitor trametinib combined with hydroxychloroquine after experiencing disease progression are consistent with the preclinical data, pointing to the clinical benefits of this regimen....
As ctDNA kinetics correlate with the response to treatment in KRAS-mutated adenocarcinoma, we anticipated that this analysis could be of interest. Materials and methods: We monitored the level of KRAS-mutated ctDNA by digital droplet PCR in serial plasma samples from two patients who had ...
The phosphoinositide 3-kinase (PI3K)–Akt axis is one of the most frequently activated pathways and is demonstrated as a therapeutic target in Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated colorectal cancer (CRC). Targeting the PI3K–Akt pathway has been a challenging undertaking through...
OPEN Citation: Cell Death and Disease (2016) 7, e2365; doi:10.1038/cddis.2016.271 Official journal of the Cell Death Differentiation Association www.nature.com/cddis Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents Olaf Klingbeil1...
variations such as EGFR,MET,ALK,ROS1 and HER2 have been identified as key drivers of NSCLC,and targeting these mutations by small molecules or monoclonal antibodies significantly improves the prognosis of NS...
The phosphoinositide 3-kinase (PI3K)–Akt axis is one of the most frequently activated pathways and is demonstrated as a therapeutic target in Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated colorectal cancer (CRC). Targeting the PI3K–Akt pathway has been a challenging undertaking through...
"Our groundbreaking Phase1bstudy targeted the KRAS-mutated mCRC patient population that has limited effective treatment options, and for whom there has been no new targeted therapy approved in decades. The Phase1bstudy revealed the sa...